Ligand Pharma up after US FDA nod for its topical skin drug

Ligand Pharmaceuticals Incorporated

05/01/2024 22:37

** Shares of Ligand Pharmaceuticals  LGND.O  rise 5.2% to
$74.5 in extended trading
    ** The firm's topical treatment for a viral skin infection
received U.S. FDA approval
    ** The gel, Zelsuvmi, is expected to be available in the
U.S. in the second half of 2024
    ** Pricing has not yet been established - company
spokesperson said in an email
    ** This marks the first-ever at-home approved treatment for
the condition in the U.S.
    ** Stocks rose 6.9% in 2023

 (Reporting by Harshita Mary Varghese in Bengaluru)
 ((HarshitaMary.Varghese@thomsonreuters.com))